Open AccessBrief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy
Author(s) -
Catherine Godfrey,
Michael D. Hughes,
Justin Ritz,
Lara E. Coelho,
Robert Gross,
Robert A. Salata,
Rosie Mngqibisa,
Carole L. Wallis,
Makanga. E. Mumbi,
Mitch Matoga,
Selvamuthu Poongulali,
Marije Van Schalkwyk,
Evelyn Hogg,
Courtney V. Fletcher,
Beatriz Grinsztejn,
Ann C. Collier
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002324
Subject(s) - regimen , lopinavir , medicine , cohort , ritonavir , viral load , cohort study , population , clinical endpoint , lopinavir/ritonavir , adverse effect , clinical trial , antiretroviral therapy , immunology , human immunodeficiency virus (hiv) , environmental health
Sex differences in studies of antiretroviral (ART) drug exposure and treatment outcomes support the hypothesis that some ART combinations may not be well tolerated in women. We evaluated disparities in outcomes between men and women participating in ACTG A5288, an interventional strategy trial for individuals failing a protease inhibitor-based second-line ART regimen in low- and middle-income countries.